ACADIA Pharmaceuticals Director Sells Shares Amidst Strong Financial Performance
San Diego, CA – September 4, 2025 – Elizabeth A. Garofalo, a Director at ACADIA Pharmaceuticals (ACAD), recently sold 1,600 shares of the company’s stock in a transaction valued at $41,552, according to a recent SEC filing. The sale comes as ACADIA Pharmaceuticals continues to demonstrate positive financial momentum, fueled by strong sales of its key medications, DAYBUE and NUPLAZID.
ACADIA Pharmaceuticals reported robust Q2 2025 earnings, achieving a 9% increase in total revenue, reaching $264.6 million. DAYBUE sales experienced a 14% year-over-year rise, while NUPLAZID sales increased by 7%, driven by successful direct-to-consumer campaigns and growing prescription numbers. The company has also bolstered its long-term prospects through pipeline expansion – currently encompassing nine programs - and favorable patent litigation outcomes securing market exclusivity for NUPLAZID.Despite increased spending on selling, general, and administrative expenses (SG&A) and inherent risks associated with pipeline development, ACADIA raised its full-year revenue guidance for NUPLAZID, signaling confidence in its continued growth.
According to TipRanks’ AI Analyst, Spark, ACAD currently receives an “Outperform” rating. Spark’s analysis highlights the company’s strong financial performance, positive earnings call insights, and reasonable valuation. While technical analysis is limited due to data availability, the overall assessment points to a well-positioned company with significant growth potential.
Key ACADIA Pharmaceuticals Metrics (as of September 4, 2025):
Year-to-Date Price Performance: 37.67%
Average Trading Volume: 1,908,488
Technical Sentiment Signal: Buy
Current Market Capitalization: $4.38 Billion
